Clinical trials: House Dust Mite Allergy
Rhinitis, Allergic, Perennial, Rhinitis, Allergic, Nonseasonal
Safety Study of MK-8237 Treatment in House-Dust-Mite Allergic Adolescents (MK-8237-008)
The purpose of this study is to evaluate the safety of two doses (6 Development Units [DU] and 12 DU) of MK-8237 sublingual tablets compared to Placebo in adolescents with house dust mite-induced allergic…
- Trial name
- NCT01678807
- Testing
- MK-8237 6 DU, MK-8237 12 DU
- Volunteers
- 195 people
- Sponsor
- ALK-Abelló A/S
Asthma
Immunotherapy Administered Under the Tongue to Treat Dust Mite Allergy
This study will investigate sublingual immunotherapy (SLIT), a treatment involving antigens placement under the tongue to help asthma sufferers build a tolerance to the allergy-causing substances.
- Trial name
- NCT00200850
- Testing
- House Dust Mite SLIT, High dose SLIT
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Wisconsin, Madison
Asthma, COPD
The Effect of FP-025, on Allergen-induced Airway Responses in Mild Eosinophilic House Dust Mite (HDM)-Allergic Asthma.
This study is a Phase IIa, randomized, placebo-controlled, double-blind, 2-way crossover, 2-center (conducted in EU; The Netherlands) study in male and female subjects with stable, mild HDM-allergic asthma.
- Trial name
- NCT03858686
- Testing
- FP-025 capsules
- Where
- 2 sites in Netherlands
- Volunteers
- 27 people
- Sponsor
- Foresee Pharmaceuticals Co., Ltd.